新型喘治疗:超越已批准的喘新型升级疗法
Lior Seluk1, Andrea E Davis2, Sarah Rhoads2
1Division of Pulmonary, Critical Care, and Sleep Medicine, National Jewish Health, Denver, Colorado.
严重喘的治疗已经发展成为有针对性的生物疗法,包括单克隆抗体. 虽然有效,但研究仍在继续寻找新的治疗方法,以解决剩余的未满足需求,并个性化护理,以获得更好的患者结果.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在过去的20年里,严重喘的治疗从一般治疗转向了向性生物疗法.
- 针对特定分子通路的单克隆抗体已经改变了对严重喘患者的护理.
研究的目的:
- 审查严重喘管理的演变.
- 突出目前的生物疗法,并探索难以治疗喘的新兴治疗方法.
- 讨论个性化喘护理的未来方向.
主要方法:
- 关于喘管理和生物治疗的科学文献的综述.
- 已批准的单克隆抗体和正在进行的临床试验的分析.
- 讨论新的分子标和创新的治疗策略.
主要成果:
- 针对IgE,IL-5,IL-5受体,IL-4/13受体和TSLP的生物药物改善了严重喘的症状并减少了严重喘的恶化.
- 尽管取得了进展,但许多患者仍然经历了恶化,需要口服皮质类固醇.
- 针对细胞因子,酶和细胞通路的新疗法正在开发中,包括吸入和组合生物制剂.
结论:
- 目前的生物疗法已经显著提升了严重喘护理,但仍然存在未满足的需求.
- 对新的分子点和创新的治疗方法的持续研究对未来的喘管理有希望.
- 个性化治疗策略对于优化严重喘患者的治疗结果至关重要.
更多相关视频
07:28Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
04:03Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD
Published on: September 27, 2024
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma-IV: Nursing Management
First, in...
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
COPD: Management Using Bronchodilators and Corticosteroids
